8 Oct 2020 07:00
Yourgene Health plc
("Yourgene Health" or the "Company")
Strategic reproductive health partnership secured in Japan
Manchester, UK - 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene's FlexTM Analysis Software ("Flex Software") bioinformatics platform for a reproductive health project.
Yourgene and the Japanese partner (the "Partner") have entered into a technology transfer agreement which provides the Partner with access to Yourgene's bioinformatics platform, the FlexTM Analysis Software, and other associated knowhow ("Knowhow"). The Flex Software and Knowhow will enable the Partner to offer in-house bioinformatic analysis and clinical screening services to the Japanese market for a reproductive health application. Yourgene expects this partnership to deliver over USD2.5m of revenue over the contract life, as well as creating a benchmark clinical offering in this major world healthcare market.
Yourgene launched its Yourgene FlexTM Analysis Software, a medical grade, configurable bioinformatics software platform in October 2019, to support the Company's ambition to develop strategic in vitro diagnostic (IVD) product development partnerships and research collaborations with key industry players. The Flex Software allows the complex sequencing data, generated during lab workflow, to be analysed in order to produce a user friendly, easy to interpret report for clinicians, without the need for the geneticist or a bioinformation. The Partner will also take a licence for the Atlas Workflow Manager, which ensures a seamless sample tracking workflow that will link to the Flex Software.
The Company will update the market with further information in due course when the results of this collaboration are ready for commercial launch by the Partner in Japan.
For more information on Yourgene's FlexTM Analysis Software please visit:
https://www.yourgene-health.com/yourgene-flex-analysis-software
Lyn Rees, CEO of Yourgene Health plc, commented: "We are delighted to have secured this key strategic partnership expanding and consolidating our geographical reach into Japan. This is a great endorsement of our analytical capabilities, and we are pleased to be able to customise these class-leading technology tools: Flex Software and Atlas Workflow Manager for our partner. We hope to develop future collaborations with this blue chip partner further across reproductive health and other fields."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | ||
Barry Hextall, Chief Financial Officer |
| ||
Joanne Cross, Director of Marketing |
| ||
|
| ||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | ||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| ||
|
| ||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | ||
Aubrey Powell / Tom Salvesen / George Tzimas |
| ||
|
| ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | ||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| ||
|
| ||
|
| ||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | ||
|
|
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.